In light of the potential benefit of maintenance oral etoposide in extensive SCLC, it would be reasonable to assess whether adding maintenance oral etoposide to a maintenance PD-1/PD-L1 inhibitor would be of value. Here, CD274 is linked to small cell lung carcinoma.